All Stories

Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO

Caris recently began rolling out its MI Cancer Seek companion diagnostic test for genomic tumor profiling.

Jun 9, 2025 - 17:40
 0
Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO
Caris recently began rolling out its MI Cancer Seek companion diagnostic test for genomic tumor profiling.
Read More

Tags:

Previous Article

FDA clears Reflow Medical’s retrievable below-the-knee stent system

Next Article

Metsera shares climb on early data for amylin-targeting obesity shot

Related Posts

BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government

BioNTech pledges £1B to bolster UK presence while nabbi...

May 20, 2025  0

Eli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1B

Eli Lilly lands next-gen pain asset in SiteOne Therapeu...

May 27, 2025  0

Kinase inhibitor biotech Enliven calls time on ph. 1 HER2 solid tumor program

Kinase inhibitor biotech Enliven calls time on ph. 1 HE...

May 15, 2025  0